Core Viewpoint - The company, relying on an AI-driven synthetic biology technology platform, has developed several internationally competitive original technologies and established a rich product pipeline [1][2]. Group 1: Company Overview - Founded in 2015, the company has received over 400 million yuan in exclusive investment from Eli Lilly Asia Fund, making it one of the few synthetic biology enterprises with full-chain capabilities from R&D to production and commercialization [2]. - The company operates from its headquarters in Suzhou, with dual R&D centers in China and the U.S., and production bases in Hunan and Anhui, achieving an annual comprehensive production capacity exceeding 10,000 tons [3]. Group 2: Product and Market Development - The company has achieved stable supply and large-scale production of key raw materials, including the antibiotic raw material Florfenicol, pharmaceutical intermediates like NMN/NAD, and animal nutrition raw materials such as 25-hydroxyvitamin D3 [5]. - Its products are exported to over 20 countries globally, with a continuous increase in market share [1]. Group 3: Industry Events - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, focusing on AI-enabled biological manufacturing and featuring discussions on green chemicals, new materials, future food, and agriculture [8][9].